Ampio Pharmaceuticals, Inc

(NYSE MKT:AMPE)

Latest On Ampio Pharmaceuticals, Inc (AMPE):

Date/Time Type Description Signal Details
2023-04-18 20:27 ESTNewsAmpio stock jumps ~20% after CEO letter on drug program, reorganizationN/A
2022-12-28 09:04 ESTNewsAmpio Pharmaceuticals regains listing complianceN/A
2022-11-09 02:12 ESTNewsAmpio Pharmaceuticals to implement 1-for-15 reverse stock splitN/A
2022-08-03 17:17 ESTNewsAmpio announces 55% reduction of staff as key development program endsN/A
2022-06-02 21:40 ESTNewsAmpio drops amid plans to end studies for COVID-19 therapyN/A
2022-05-17 03:16 ESTNewsAmpio Pharmaceuticals GAAP EPS of -$0.03 misses by $0.01N/A
2022-04-21 15:05 ESTNewsAmpio stock slumps 33% as FDA disagrees with changes to trial, unblinding data for pain drug AmpionN/A
2022-03-29 21:52 ESTNewsAmpio Pharmaceuticals Q4 2021 Earnings PreviewN/A
2022-03-29 21:50 ESTNewsAmpio Pharmaceuticals GAAP EPS of -$0.10N/A
2022-03-29 21:50 ESTNewsAmpio Pharmaceuticals, Inc. (AMPE) CEO Michael Martino on Q4 2021 Results - Earnings Call TranscriptN/A
2021-12-13 15:14 ESTNewsAmpio Pharmaceuticals prices $22.5M stock offeringN/A
2021-11-22 18:57 ESTNewsAmpio Pharmaceuticals CEO Mike Macaluso to take one-year leave of absenceN/A
2021-11-11 01:09 ESTNewsWarning: AMPE is at high risk of performing badlyN/A
2021-11-11 01:05 ESTNewsAmpio Pharmaceuticals, Inc. (AMPE) Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-10 02:27 ESTNewsAmpio Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-10-13 17:02 ESTNewsAmpio bolsters C-suite; appoints new chief medical officerN/A
2021-10-07 04:29 ESTNewsAMPE is at high risk of performing badlyN/A
2021-09-30 09:12 ESTNewsWarning: AMPE has been downgraded to Very BearishN/A
2021-09-24 22:13 ESTNewsWarning: AMPE has been downgraded to Very Bearish.N/A
2021-09-21 11:46 ESTNewsAmpio Pharmaceuticals gets regulatory greenlight for Ampion COVID-19 study in IndiaN/A
2021-09-17 13:25 ESTNewsAmpio Pharmaceuticals shares rise after top-line results from late-stage Ampion studyN/A
2021-08-04 23:32 ESTNewsAmpio Pharmaceuticals, Inc. (AMPE) CEO Mike Macaluso on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-20 19:24 ESTNewsAmpio Pharmaceuticals: Regulatory Process Taking Too LongN/A
2021-07-20 19:07 ESTNewsAmpio Pharma stock surge 33% on AP-019 Phase II study expansion to IndiaN/A
2021-07-20 19:06 ESTNewsAmpio highlights integrated data from Ampion osteoarthritis of the knee trialsN/A
2021-07-20 19:05 ESTNewsAmpio Pharmaceuticals to join Russell 2000 and Russell 3000 IndexN/A
2021-07-20 19:01 ESTNewsAmpio Pharmaceuticals starts dosing in mid-stage Ampion COVID-19 trialN/A
2021-04-27 12:03 ESTNewsAmpio Pharma's Ampion reduces mortality nearly 80% in COVID-19N/A
2021-04-06 16:42 ESTNewsAmpio posts encouraging results from Ampion COVID-19 pre-clinical studyN/A
2021-03-16 19:20 ESTNewsAmpio Pharmaceuticals posts early positive results in inhaled Ampion COVID-19 trialN/A
2021-03-16 19:20 ESTNewsAmpio surges 7.5% on phase 1 data for COVID-19 respiratory treatmentN/A
2021-03-05 07:06 ESTEarnings EstimateAn EPS average of -$0.02 is estimated for the quarter ending on March 31, 2021.Sell
2021-03-05 07:06 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the 2022 year.Sell
2021-03-05 07:06 ESTEarnings EstimateAn EPS average of -$0.02 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-04 17:34 ESTNewsAmpio Pharmaceuticals' (AMPE) CEO Mike Macaluso on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-04 07:05 ESTFinancialsCompany financials have been released.Neutral
2021-03-03 21:59 ESTNewsAmpio Pharmaceuticals EPS in-lineN/A
2021-02-23 09:57 ESTNewsAmpio adds new Ampion COVID-19 trial sitesN/A
2021-02-12 14:30 ESTNewsAmpio: Short-Term Triple-Digit Upside From Ampion's Progressing Phase 3 Drug ApplicationN/A
2021-02-01 09:37 ESTNewsAmpio posts early positive data from phase 1 COVID-19 respiratory distress trialN/A
2021-01-15 07:06 ESTNewsAmpio Pharma updates on phase I trial enrolment for COVID-19 ampion studyN/A
2021-01-04 21:08 ESTNewsAmpion updates on COVID-19 trial progressN/A
2020-12-29 12:51 ESTNewsAmpio cleared to complete Phase 3 study for osteoarthritisN/A
2020-12-18 07:31 ESTNewsAmpio Pharms's IV Ampion demonstrates safety in COVID-19 studyN/A
2020-12-13 03:10 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 15:09 ESTFinancialsCompany financials have been released.Neutral
2020-12-11 01:43 ESTNewsAmpio inks research pact explore new indications for AmpionN/A
2020-12-02 15:54 ESTNewsAmpio Pharmaceuticals to complete enrollment in early-stage with inhaled Ampion in COVID-19 patientsN/A
2020-11-25 17:37 ESTNewsAmpio updates on Phase 1 study with inhaled Ampion in COVID-19 patientsN/A
2020-11-15 11:08 ESTFinancialsCompany financials have been released.Neutral

About Ampio Pharmaceuticals, Inc (AMPE):

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.

AMPE Quotes by TradingView

See Advanced Chart

General

  • Name Ampio Pharmaceuticals, Inc
  • Symbol AMPE
  • Type Common Stock
  • Exchange NYSE MKT
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 18
  • Last Split Factor1:3
  • Last Split Date2008-08-01
  • Fiscal Year EndDecember
  • IPO Date2010-03-31
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.ampiopharma.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 20.33
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.09
  • Next Year EPS Estimate -$0.08
  • Return on Assets -54%
  • Return on Equity -133%
  • Earnings Per Share $0.01
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 356.04 million
  • EBITDA -9419476
  • Analyst Target Price $4.5
  • Book Value Per Share $0.09
View More

Share Statistics

  • Shares Outstanding 195.63 million
  • Shares Float 193.02 million
  • % Held by Insiders 760%
  • % Held by Institutions 12.01%
  • Shares Short 21.02 million
  • Shares Short Prior Month 22.89 million
  • Short Ratio 4.56
  • Short % of Float 11%
  • Short % of Shares Outstanding 11%
View More

Technicals

  • Beta 1.75
  • 52 Week High $2.98
  • 52 Week Low $0.31
  • 50 Day Moving Average 1.82
  • 200 Day Moving Average 1.29
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Ampio Pharmaceuticals, Inc (AMPE) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Ampio Pharmaceuticals, Inc (AMPE) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-03$N/A-$0.02-$0.020%
2020-09-302020-11-03$N/A-$0.02
2020-06-302020-07-31$N/A-$0.02-$0.0450.75%
2020-03-312020-05-06$N/A-$0.03-$0.0425%
2019-12-312020-02-21$N/A-$0.01-$0.0471.43%
2019-09-302019-11-07$N/A-$0.05-$0.04-25%
2019-06-302019-08-09$N/A-$0.03
2019-03-312019-05-10$N/A-$0.05
2018-12-312019-03-18$N/A$0.01
2018-09-302018-11-14$N/A$0.06
2018-06-302018-08-13$N/A$0.05
2018-03-312018-05-10$N/A$0.27
2017-12-312018-03-06$N/A-$0.58
2017-09-302017-11-07$N/A-$0.06
2017-06-302017-08-09$N/A-$0.04
2017-03-312017-05-12$N/A-$0.03
2016-12-312017-03-16$N/A-$0.06
2016-09-302016-11-08$N/A-$0.07
2016-06-302016-08-31$N/A-$0.10
2016-03-312016-06-01$N/A-$0.13
2015-12-312016-03-02$469213-$0.19
2015-09-302015-12-02$487385-$0.14
2015-06-302015-09-02$184435-$0.14
2015-03-312015-06-03$21429-$0.14
2014-12-312015-02-24$22000-$0.19-$0.190%
2014-09-302014-11-07$21000-$0.18-$0.2010%
2014-06-302014-08-08$21000-$0.17-$0.2839.29%
2014-03-312014-05-07$13000-$0.23-$0.17-35.29%
2013-12-312014-02-14$12000-$0.18-$0.16-12.5%
2013-09-302013-11-08$13000-$0.16-$0.175.88%
2013-06-302013-08-09$12000-$0.17-$0.11-54.55%
2013-03-312013-05-03$13000-$0.11-$0.09-22.22%
2012-12-312013-03-05$12000-$0.10-$0.08-25%
2012-09-302012-11-02$13000-$0.07-$0.070%
2012-06-302012-08-29$12000-$0.08
2012-03-312012-05-30$13000-$0.09
2011-12-312011-12-31$13000-$0.16
2011-09-302011-09-30$6000-$0.09
2011-06-302011-06-30$N/A-$0.10
2011-03-312011-03-31$N/A-$0.49
2010-12-312010-12-31$N/A-$0.18
2010-09-302010-09-30$N/A-$0.14
2010-06-302010-06-30$N/A-$0.07
2010-03-312010-03-31$N/A-$0.11
2009-12-312009-12-31$N/A-$0.01
2009-09-302009-09-30$N/A-$0.01
2009-06-302009-06-30$N/A-$0.01
2009-03-312009-03-31$N/A-$0.01
2008-12-312008-12-31-$0.01
2008-09-302008-09-30-$0.01

Ampio Pharmaceuticals, Inc (AMPE) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 2.15 million N/A N/A 4.25 million 5.49 million
Income Before Tax -4.62 million N/A N/A -5.18 million -1.02 million
Selling General Administrative 1.77 million N/A N/A 1.76 million 1.65 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -4.62 million N/A N/A -5.73 million -7.15 million
Operating Income -3.91 million N/A N/A -6.02 million -7.15 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 831000 6.13 million
Net Income From Continuing Operations -4.62 million N/A N/A -5.18 million -1.02 million
Net Income Applicable to Common Shares -4.62 million -3.37 million -2.73 million -5.18 million -1.02 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities -627000 -1.95 million 189000 1.89 million 249838
Total Cash Flow from Investing Activities -48000 N/A N/A -7880 -530
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A 436000 3.25 million -250
Change to Operating Activities 451000 -403000 680000 100541 -308335
Change in Cash N/A N/A -4.12 million -1.51 million -4.74 million
Total Cash from Operating Activities -2.71 million -4.59 million -4.55 million -4.75 million -4.74 million
Depreciation N/A N/A 295000 173705 239099
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -315000 -314000 -246000 -276299 -250
Change to Net Income 543000 239000 -538000 -5.9 million 2.3 million
Capital Expenditures N/A N/A N/A 7880 530
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 5.37 million N/A N/A 6.85 million 7.56 million
Total Stockholder Equity 17.51 million N/A N/A 1.99 million 6.44 million
Other Current Liabilities 284000 N/A N/A N/A N/A
Total Assets 22.88 million N/A N/A 8.85 million 14 million
Common Stock 19000 18000 17000 16000 16000
Other Current Assets 1.15 million N/A N/A 310000 N/A
Retained Earnings -200.53 million -195.91 million -192.54 million -189.81 million -184.63 million
Other Liabilities N/A 1.9 million 1.91 million 1.23 million 2.06 million
Other Assets N/A N/A N/A N/A N/A
Cash 17.35 million N/A N/A 2.42 million 6.53 million
Total Current Liabilities 1.83 million 1.92 million N/A 4.48 million 4.28 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 3.56 million 4.71 million 5.07 million 5.41 million 5.75 million
Total Current Assets 18.49 million 10.84 million N/A 3.44 million 8.25 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 17.51 million 10.73 million 6.34 million 1.99 million 6.44 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.55 million 1.64 million N/A 1.23 million 4.03 million

Ampio Pharmaceuticals, Inc (AMPE) Chart:

Ampio Pharmaceuticals, Inc (AMPE) News:

Below you will find a list of latest news for Ampio Pharmaceuticals, Inc (AMPE) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Ampio Pharmaceuticals, Inc (AMPE) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest AMPE Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST1$0.2213
Jun 13, 2022 7:59 PM EST400$0.22
Jun 13, 2022 7:59 PM EST100$0.22
Jun 13, 2022 7:59 PM EST93$0.22
Jun 13, 2022 7:59 PM EST180$0.22

Ampio Pharmaceuticals, Inc (AMPE) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020007625/0001558370-20-007625-index.htm
2019-12-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1411906/000000000019016594/0000000000-19-016594-index.htm
2020-01-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1411906/000000000020000410/0000000000-20-000410-index.htm
2020-04-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1411906/000000000020003564/0000000000-20-003564-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000021545719006619/0000215457-19-006619-index.htm
2019-03-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000021545719007617/0000215457-19-007617-index.htm
2019-06-20SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000090266419002827/0000902664-19-002827-index.htm
2020-01-23SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000090266420000409/0000902664-20-000409-index.htm
2017-10-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000110465917064390/0001104659-17-064390-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000110465918008948/0001104659-18-008948-index.htm
2018-08-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000110465918051166/0001104659-18-051166-index.htm
2018-08-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000110465918052561/0001104659-18-052561-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000110465919008603/0001104659-19-008603-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000110465920023386/0001104659-20-023386-index.htm
2020-02-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000110465920023617/0001104659-20-023617-index.htm
2017-10-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420417052534/0001144204-17-052534-index.htm
2017-10-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000114420417052841/0001144204-17-052841-index.htm
2017-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000114420417056691/0001144204-17-056691-index.htm
2017-11-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420417059835/0001144204-17-059835-index.htm
2017-12-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420417065540/0001144204-17-065540-index.htm
2018-01-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418001170/0001144204-18-001170-index.htm
2018-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1411906/000114420418013087/0001144204-18-013087-index.htm
2018-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418020719/0001144204-18-020719-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000114420418026799/0001144204-18-026799-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418042492/0001144204-18-042492-index.htm
2018-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000114420418044117/0001144204-18-044117-index.htm
2018-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418047875/0001144204-18-047875-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418052136/0001144204-18-052136-index.htm
2018-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418052429/0001144204-18-052429-index.htm
2018-10-31DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1411906/000114420418056277/0001144204-18-056277-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000114420418059508/0001144204-18-059508-index.htm
2018-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418063673/0001144204-18-063673-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418064144/0001144204-18-064144-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420418065498/0001144204-18-065498-index.htm
2019-06-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420419030839/0001144204-19-030839-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420419030900/0001144204-19-030900-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420419030984/0001144204-19-030984-index.htm
2019-06-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000114420419031062/0001144204-19-031062-index.htm
2019-06-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000114420419031078/0001144204-19-031078-index.htm
2019-06-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000114420419031100/0001144204-19-031100-index.htm
2019-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000114420419031107/0001144204-19-031107-index.htm
2018-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000119312518007294/0001193125-18-007294-index.htm
2018-08-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000119312518242952/0001193125-18-242952-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000119312518242958/0001193125-18-242958-index.htm
2018-08-10FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1411906/000119312518246101/0001193125-18-246101-index.htm
2018-08-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000119312518246282/0001193125-18-246282-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000119312518246554/0001193125-18-246554-index.htm
2019-02-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000119312519025226/0001193125-19-025226-index.htm
2020-01-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000119312520002874/0001193125-20-002874-index.htm
2017-09-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919117054279/0001209191-17-054279-index.htm
2018-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919118005899/0001209191-18-005899-index.htm
2018-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919118005900/0001209191-18-005900-index.htm
2018-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919118005902/0001209191-18-005902-index.htm
2018-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919118052048/0001209191-18-052048-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919118053316/0001209191-18-053316-index.htm
2018-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919118053322/0001209191-18-053322-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919119002018/0001209191-19-002018-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919119002020/0001209191-19-002020-index.htm
2019-01-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919119002024/0001209191-19-002024-index.htm
2019-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919119003027/0001209191-19-003027-index.htm
2019-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919119003034/0001209191-19-003034-index.htm
2019-01-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000120919119003037/0001209191-19-003037-index.htm
2019-08-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919000889/0001415889-19-000889-index.htm
2019-08-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919000893/0001415889-19-000893-index.htm
2019-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919000949/0001415889-19-000949-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001006/0001415889-19-001006-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001009/0001415889-19-001009-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001011/0001415889-19-001011-index.htm
2019-09-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001059/0001415889-19-001059-index.htm
2019-10-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001195/0001415889-19-001195-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001555/0001415889-19-001555-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001556/0001415889-19-001556-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001557/0001415889-19-001557-index.htm
2019-12-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588919001558/0001415889-19-001558-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920000054/0001415889-20-000054-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920000055/0001415889-20-000055-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920000056/0001415889-20-000056-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920000057/0001415889-20-000057-index.htm
2020-01-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920000058/0001415889-20-000058-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920000097/0001415889-20-000097-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920001830/0001415889-20-001830-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920001832/0001415889-20-001832-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920001835/0001415889-20-001835-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920001837/0001415889-20-001837-index.htm
2020-07-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1411906/000141588920001840/0001415889-20-001840-index.htm
2019-06-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000153561019000090/0001535610-19-000090-index.htm
2020-01-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1411906/000153561020000027/0001535610-20-000027-index.htm
2019-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1411906/000155837019002244/0001558370-19-002244-index.htm
2019-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019002978/0001558370-19-002978-index.htm
2019-04-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000155837019002980/0001558370-19-002980-index.htm
2019-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019003534/0001558370-19-003534-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837019004876/0001558370-19-004876-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019005250/0001558370-19-005250-index.htm
2019-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019005791/0001558370-19-005791-index.htm
2019-07-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019006059/0001558370-19-006059-index.htm
2019-07-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019006071/0001558370-19-006071-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837019007896/0001558370-19-007896-index.htm
2019-08-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019008313/0001558370-19-008313-index.htm
2019-09-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019008672/0001558370-19-008672-index.htm
2019-10-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019008868/0001558370-19-008868-index.htm
2019-10-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1411906/000155837019008921/0001558370-19-008921-index.htm
2019-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019009236/0001558370-19-009236-index.htm
2019-10-31DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1411906/000155837019009582/0001558370-19-009582-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837019010403/0001558370-19-010403-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019011309/0001558370-19-011309-index.htm
2019-12-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837019011580/0001558370-19-011580-index.htm
2020-01-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1411906/000155837020000036/0001558370-20-000036-index.htm
2020-01-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1411906/000155837020000085/0001558370-20-000085-index.htm
2020-01-08S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1411906/000155837020000087/0001558370-20-000087-index.htm
2020-01-08S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1411906/000155837020000089/0001558370-20-000089-index.htm
2020-01-08S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1411906/000155837020000091/0001558370-20-000091-index.htm
2020-01-08S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1411906/000155837020000093/0001558370-20-000093-index.htm
2020-01-1410-Q/AQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837020000146/0001558370-20-000146-index.htm
2020-02-2110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1411906/000155837020001123/0001558370-20-001123-index.htm
2020-03-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020003045/0001558370-20-003045-index.htm
2020-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020003955/0001558370-20-003955-index.htm
2020-04-16S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411906/000155837020003966/0001558370-20-003966-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020004145/0001558370-20-004145-index.htm
2020-04-30S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1411906/000155837020004824/0001558370-20-004824-index.htm
2020-05-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1411906/000155837020004920/0001558370-20-004920-index.htm
2020-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837020005444/0001558370-20-005444-index.htm
2020-05-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1411906/000155837020005452/0001558370-20-005452-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020007625/0001558370-20-007625-index.htm
2020-07-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020008130/0001558370-20-008130-index.htm
2020-07-3110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837020008834/0001558370-20-008834-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020010968/0001558370-20-010968-index.htm
2020-10-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1411906/000155837020012119/0001558370-20-012119-index.htm
2020-10-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1411906/000155837020012122/0001558370-20-012122-index.htm
2020-11-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1411906/000155837020012324/0001558370-20-012324-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1411906/000155837020012828/0001558370-20-012828-index.htm
2020-05-06EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1411906/999999999520001064/9999999995-20-001064-index.htm

Ampio Pharmaceuticals, Inc (AMPE) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ampio Pharmaceuticals, Inc (AMPE). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 760%
Institutional Ownership: 1201%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-01-25PHILIP H COELHODirectorBuy5,747.003.4819,999.56110,474.00https://www.sec.gov/Archives/edgar/data/1411906/000120919118005899/0001209191-18-005899-index.htm
2020-01-02David R StevensDirectorBuy34,059.000.5919,999.44121,049.00https://www.sec.gov/Archives/edgar/data/1411906/000141588920000058/0001415889-20-000058-index.htm
2019-01-02PHILIP H COELHODirectorBuy45,454.000.4419,999.76155,928.00https://www.sec.gov/Archives/edgar/data/1411906/000120919119002018/0001209191-19-002018-index.htm
2020-01-02PHILIP H COELHODirectorBuy34,059.000.5919,999.44189,987.00https://www.sec.gov/Archives/edgar/data/1411906/000141588920000057/0001415889-20-000057-index.htm
2018-01-25Richard B GilesDirectorBuy5,747.003.4819,999.56221,840.00https://www.sec.gov/Archives/edgar/data/1411906/000120919118005900/0001209191-18-005900-index.htm
2019-01-02Richard B GilesDirectorBuy45,454.000.4419,999.76267,294.00https://www.sec.gov/Archives/edgar/data/1411906/000120919119002020/0001209191-19-002020-index.htm
2020-01-02Richard B GilesDirectorBuy34,059.000.5919,999.44301,353.00https://www.sec.gov/Archives/edgar/data/1411906/000141588920000055/0001415889-20-000055-index.htm
2018-01-25David R StevensDirectorBuy5,747.003.4819,999.5641,536.00https://www.sec.gov/Archives/edgar/data/1411906/000120919118005902/0001209191-18-005902-index.htm
2019-10-17David Bar-OrDirectorBuy45,228.000.4419,999.8245,228.00https://www.sec.gov/Archives/edgar/data/1411906/000141588919001195/0001415889-19-001195-index.htm
2020-01-02David Bar-OrDirectorBuy34,059.000.5919,999.4479,287.00https://www.sec.gov/Archives/edgar/data/1411906/000141588920000056/0001415889-20-000056-index.htm
2019-01-02David R StevensDirectorBuy45,454.000.4419,999.7686,990.00https://www.sec.gov/Archives/edgar/data/1411906/000120919119002024/0001209191-19-002024-index.htm